This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.

Provided is a composition of a ready-to-use injectable solution comprising pemetrexed or pharmaceutically acceptable salts thereof, containing pemetrexed; anhydrous sodium sulfite; and N-acetyl-L-cystein. With respect to use as an injectable preparation. The ready-to-use injectable solution composition is suitable for effective administration of pemetrexed since a melting process of main ingredients is not necessary before administration, and the composition can be used by being diluted immediately in a perfusate. In addition, the properties of the composition do not change even in long-term storage, and pharmaceutical stability is significantly improved by inhibiting related substances below a reference, whereby the composition can be stored in a liquid preparation state.

Provided is a composition of a ready-to-use injectable solution comprising pemetrexed or pharmaceutically acceptable salts thereof, containing pemetrexed; anhydrous sodium sulfite; and N-acetyl-L-cystein. With respect to use as an injectable preparation. The ready-to-use injectable solution composition is suitable for effective administration of pemetrexed since a melting process of main ingredients is not necessary before administration, and the composition can be used by being diluted immediately in a perfusate. In addition, the properties of the composition do not change even in long-term storage, and pharmaceutical stability is significantly improved by inhibiting related substances below a reference, whereby the composition can be stored in a liquid preparation state.

The present disclosure provides methods, kits, and compositions comprising β-alethine and one or more immune modulators and methods to determine when they are advantageous. Particular applications include the use of β-alethine and one or more immune modulators in the treatment of cancer.

The present disclosure provides methods, kits, and compositions comprising β-alethine and one or more immune modulators and methods to determine when they are advantageous. Particular applications include the use of β-alethine and one or more immune modulators in the treatment of cancer.

The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons.

The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons.

The present invention provides methods for dilating the bronchi or bronchioles and relaxing a pulmonary smooth muscle in a subject by treating the subject with a pharmaceutical composition, which includes a Histone deacetylase (HDAC) inhibitor. The ability to dilate the bronchi or bronchioles and relax a pulmonary smooth muscle according to the methods of the invention allows treating, alleviating, or inhibiting bronchoconstrictive diseases or disorders and symptoms associated or derived from bronchoconstrictive diseases.

The present invention provides methods for dilating the bronchi or bronchioles and relaxing a pulmonary smooth muscle in a subject by treating the subject with a pharmaceutical composition, which includes a Histone deacetylase (HDAC) inhibitor. The ability to dilate the bronchi or bronchioles and relax a pulmonary smooth muscle according to the methods of the invention allows treating, alleviating, or inhibiting bronchoconstrictive diseases or disorders and symptoms associated or derived from bronchoconstrictive diseases.